This move is archived. Current quotes and coverage live on the stock page.
Follow CSCI
Investors are taking notice as COSCIENS Biopharma Inc. sees a notable uptick in its stock price.
COSCIENS Biopharma Inc. (CSCI.TO) is experiencing a positive turn in its stock performance, rising by 3.15% in today’s trading session. The stock closed at CA$7.86, reflecting growing investor interest.
Advertisement
COSCIENS Biopharma Inc.
CSCI.TO
CSCI.TO
COSCIENS Biopharma Inc.
WealthAwesomeMarket cap
$9.15M
52W high
$14.80
52W low
$3.30
1W change
-0.76%
Beta
1.80
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CSCI's historical volatility
30-Day Vol
62.5%
Annualized
90-Day Vol
335.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$10.97
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.74 | C$7.85 – C$12.09 |
| 60 trading days | C$10.34 | C$7.62 – C$14.03 |
| 90 trading days | C$10.97 | C$7.56 – C$15.94 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The rise in COSCIENS Biopharma's stock may signal renewed confidence among investors, despite the company's recent challenges.
Stock Price Increase of 3.15%
COSCIENS Biopharma's market cap stands at CA$7.69 million, indicating it is still a small-cap player in the biopharma sector.
Bull case
This increase in stock price could be seen as a sign that investors are feeling more confident about the company’s future. This comes after COSCIENS reported a net income of $10.8 million, which is a positive indicator for potential growth.
Bear case
However, it’s important for potential investors to stay cautious. The company has faced issues in the past, including a management cease trade order and delays in financial filings, which could pose risks.
Advertisement
Recent Performance Overview
COSCIENS Biopharma Inc. has seen its stock rise by 3.15% today, reaching a closing price of CA$7.86. This increase comes amid a backdrop of recent financial disclosures that highlight a net income of CA$10.8 million for Q1 2026, primarily driven by income from discontinued operations.
Market Sentiment and Future Outlook
Despite the positive movement in stock price, investors should remain vigilant. The company has faced challenges, including a management cease trade order due to potential delays in financial filings. This backdrop makes the stock's rise today noteworthy but also calls for careful consideration of the associated risks. For more insights, check out the full details on COSCIENS Biopharma Inc..
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
